4SC AG - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

4SC AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, '4SC AG - Product Pipeline Review - 2014', provides an overview of the 4SC AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of 4SC AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of 4SC AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of 4SC AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the 4SC AG's pipeline products

Reasons to buy

- Evaluate 4SC AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of 4SC AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the 4SC AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of 4SC AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of 4SC AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of 4SC AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
4SC AG Snapshot 6
4SC AG Overview 6
Key Information 6
Key Facts 6
4SC AG - Research and Development Overview 7
Key Therapeutic Areas 7
4SC AG - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
4SC AG - Pipeline Products Glance 17
4SC AG - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
4SC AG - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
4SC AG - Drug Profiles 21
resminostat 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
vidofludimus 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
4SC-202 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
4SC-205 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
4SC-302 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
4SC-X09 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CR-2408 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule To Inhibit RORgammat for CNS, Autoimmune And Gastrointestinal Disorders 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Modulate Cytokine for Psoriasis 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Activate TLR 8 for Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Agonise TLR 7 for Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SC-92366 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule To Inhibit Hedgehog for Cancer 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule To Inhibit Kv1.3 For Autoimmune Disease 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule To Inhibit Wnt Pathway for Cancer 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for Neurological Disorders 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules Targeting Cancer Stem Cells for Oncology 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules Targeting Epigenetic Target for Oncology 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
4SC AG - Pipeline Analysis 47
4SC AG - Pipeline Products by Target 47
4SC AG - Pipeline Products by Route of Administration 49
4SC AG - Pipeline Products by Molecule Type 50
4SC AG - Pipeline Products by Mechanism of Action 51
4SC AG - Recent Pipeline Updates 53
4SC AG - Dormant Projects 61
4SC AG - Discontinued Pipeline Products 62
Discontinued Pipeline Product Profiles 62
4SC-203 62
4SC-207 62
4SC AG - Company Statement 63
4SC AG - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables
4SC AG, Key Information 6
4SC AG, Key Facts 6
4SC AG - Pipeline by Indication, 2014 9
4SC AG - Pipeline by Stage of Development, 2014 11
4SC AG - Monotherapy Products in Pipeline, 2014 12
4SC AG - Partnered Products in Pipeline, 2014 13
4SC AG - Partnered Products/ Combination Treatment Modalities, 2014 14
4SC AG - Out-Licensed Products in Pipeline, 2014 15
4SC AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 16
4SC AG - Phase II, 2014 17
4SC AG - Phase I, 2014 18
4SC AG - Preclinical, 2014 19
4SC AG - Discovery, 2014 20
4SC AG - Pipeline by Target, 2014 48
4SC AG - Pipeline by Route of Administration, 2014 49
4SC AG - Pipeline by Molecule Type, 2014 50
4SC AG - Pipeline Products by Mechanism of Action, 2014 52
4SC AG - Recent Pipeline Updates, 2014 53
4SC AG - Dormant Developmental Projects,2014 61
4SC AG - Discontinued Pipeline Products, 2014 62
4SC AG, Subsidiaries 64